Drugs / OCT-598
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07358806 | Dec 2025 → Dec 2027 expected | breast cancer, gastroesophageal cancer, head and neck cancer, non-small cell lung carcinoma +1 | Oscotec Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OCT-598 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07358806 ↗ |
| Route | Oral | “OCT-598 will be administered orally once daily.” NCT07358806 ↗ |